相似文献
1
Exploring the molecular mechanisms between lymphoma and myelofibrosis.
Am J Transl Res. 2024 Mar 15;16(3):730-737. doi: 10.62347/NWJO7078. eCollection 2024.
2
Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies.
Haematologica. 2016 Jun;101(6):660-71. doi: 10.3324/haematol.2015.141283.
3
Megakaryocytes Are Regulators of the Tumor Microenvironment and Malignant Hematopoietic Progenitor Cells in Myelofibrosis.
Front Oncol. 2022 May 11;12:906698. doi: 10.3389/fonc.2022.906698. eCollection 2022.
4
Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements.
Cancers (Basel). 2024 Jan 25;16(3):514. doi: 10.3390/cancers16030514.
5
[18F-FDG-PET/CT is effective in distinguishing myelofibrosis due to bone marrow infiltration of diffuse large B-cell lymphoma from triple-negative primary myelofibrosis].
Rinsho Ketsueki. 2017;58(3):228-232. doi: 10.11406/rinketsu.58.228.
6
Bone marrow as a target organ of systemic lupus erythematosus: analysis of cases with myelofibrosis.
Int J Rheum Dis. 2018 May;21(5):1049-1059. doi: 10.1111/1756-185X.13308. Epub 2018 Apr 19.
7
[Pathological Characteristics of Bone Marrow in Multiple Myeloma Patients with Secondary Myelofibrosis and Their Relationship with Prognosis].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Aug;25(4):1080-1085. doi: 10.7534/j.issn.1009-2137.2017.04.021.
8
Myelosuppression toxicity of palliative splenic irradiation in myelofibrosis and malignant lymphoma.
Hematology. 2015 May;20(4):203-7. doi: 10.1179/1607845414Y.0000000192. Epub 2014 Aug 17.
9
[Pathological Characteristics of Bone Marrow in Non-Hodgkin's Lymphoma Patients with Secondary Myelofibrosis and Their Relationship with Prognosis].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015 Jun;23(3):674-8. doi: 10.7534/j.issn.1009-2137.2015.03.014.
10
Novel myelofibrosis treatment strategies: potential partners for combination therapies.
Leukemia. 2014 Nov;28(11):2139-47. doi: 10.1038/leu.2014.176. Epub 2014 Jun 3.
引用本文的文献
1
F-FDG PET/CT findings in a mucosa-associated lymphoid tissue lymphoma patient coexisting with primary myelofibrosis.
Am J Nucl Med Mol Imaging. 2024 Dec 15;14(6):365-370. doi: 10.62347/BZUZ7442. eCollection 2024.
本文引用的文献
1
Mutations, inflammation and phenotype of myeloproliferative neoplasms.
Front Oncol. 2023 May 22;13:1196817. doi: 10.3389/fonc.2023.1196817. eCollection 2023.
2
NF-κB in monocytes and macrophages - an inflammatory master regulator in multitalented immune cells.
Front Immunol. 2023 Feb 23;14:1134661. doi: 10.3389/fimmu.2023.1134661. eCollection 2023.
3
JAK/STAT pathway: Extracellular signals, diseases, immunity, and therapeutic regimens.
Front Bioeng Biotechnol. 2023 Feb 23;11:1110765. doi: 10.3389/fbioe.2023.1110765. eCollection 2023.
4
Baricitinib Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice by Inhibiting TGF-β1 Signaling Pathway.
Molecules. 2023 Feb 27;28(5):2195. doi: 10.3390/molecules28052195.
5
CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis.
Blood. 2023 May 18;141(20):2508-2519. doi: 10.1182/blood.2022015418.
6
The Role of JAK/STAT Pathway in Fibrotic Diseases: Molecular and Cellular Mechanisms.
Biomolecules. 2023 Jan 6;13(1):119. doi: 10.3390/biom13010119.
7
IL-13/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms.
Blood. 2022 Dec 29;140(26):2805-2817. doi: 10.1182/blood.2022017326.
8
Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm.
Nat Commun. 2022 Sep 13;13(1):5347. doi: 10.1038/s41467-022-32928-3.
9
GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes.
Cell Death Dis. 2022 May 20;13(5):481. doi: 10.1038/s41419-022-04932-4.
10
Defining disease modification in myelofibrosis in the era of targeted therapy.
Cancer. 2022 Jul 1;128(13):2420-2432. doi: 10.1002/cncr.34205. Epub 2022 May 2.
Zotero 插件